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Purpose
We evaluated the role of adjuvant therapy in stage IIIA endometrioid adenocarcinoma 
patients who underwent surgery followed by radiotherapy (RT) alone or chemoradiotherapy
(CTRT) according to risk group.
Materials and Methods
A multicenter retrospective study was conducted including patients with surgical stage IIIA
endometrial cancer treated by radical surgery and adjuvant RT or CTRT. Disease-free survival
(DFS) and overall survival (OS) were analyzed.
Results
Ninety-three patients with stage IIIA disease were identified. Nineteen patients (20.4%) 
experienced recurrence, mostly distant metastasis (17.2%). Combined CTRT did not affect
DFS (74.1% vs. 82.4%, p=0.130) or OS (96.3% vs. 91.9%, p=0.262) in stage IIIA disease
compared with RT alone. Patients with age ! 60 years, grade G2/3, and lymphovascular
space involvement had a significantly worse DFS and those variables were defined as risk
factors. The high-risk group showed a significant reduction in 5-year DFS (! 2 risk factors)
(49.0% vs. 88.0%, p < 0.001) compared with the low-risk group (< 2). Multivariate analysis
confirmed that more than one risk factor was the only predictor of worse DFS (hazard ratio,
5.45; 95% confidence interval, 2.12 to 13.98; p < 0.001). Of patients with no risk factors,
a subset treated with RT alone showed an excellent 5-year DFS and OS (93.8% and 100%,
respectively).
Conclusion
We identified a low-risk subset of stage IIIA endometrioid adenocarcinoma patients who
might be reasonable candidates for adjuvant RT alone. Further randomized studies are
needed to determine which subset might benefit from combined CTRT.
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Introduction
Stage IIIA endometrial cancer represents a wide range of
tumor involvement, including the uterine serosa, adnexa,
parametria, and peritoneal space, based on the staging sys-
tem of the International Federation of Gynecology and 
Obstetrics (FIGO) in 1988 [1-3]. This variability might have
an influence on survival for stage IIIA endometrial cancer.
In addition, the heterogeneity of histology, such as papillary
serous or clear cell carcinoma, makes it difficult to compare
outcomes between studies. This variability has led to a wide
range of 5-year overall survival (OS) rates for stage IIIA 
endometrial cancer, varying from 39% to 76% [3-6].
The optimal adjuvant management for patients with 
advanced endometrial cancer has yet to be defined, particu-
larly for IIIA patients as incidence is low, representing only
2.6% of patients with endometrial cancer [7]. Radiotherapy
(RT) has traditionally been employed in advanced endome-
trial carcinoma to improve locoregional control [8,9]. Several
studies have evaluated the role of combined modality adju-
vant therapy compared with a single modality in advanced
endometrial cancer and have suggested that combined
chemoradiotherapy (CTRT) can provide additional benefits
compared with computed tomography (CT) or RT alone 
[10-13]. In contrast, a randomized study failed to show an
improvement in disease-free survival (DFS) and OS in 
patients treated with combined CTRT compared with adju-
vant RT alone for high-risk endometrial cancer [14]. Those
studies included only a small proportion of stage IIIA 
patients. Thus, the effects of different adjuvant therapies for
stage IIIA endometrial cancer remain controversial. In addi-
tion, these previous studies involved a small portion of IIIA
populations, patient’s stage was determined based on the
1988 FIGO stage, and both endometriod and non-endometri-
oid adenocarcinoma were included. 
The current study included a group of patients with stage
IIIA endometrioid adenocarcinoma with favorable histology
only, using the revised 2009 FIGO stage to overcome the
aforementioned variabilities. The revised FIGO IIIA, which
was published in 2009, excluded positive peritoneal cytology
alone and denoted parametrial involvement separately as
stage IIIB. Several studies have attempted to analyze risk fac-
tors for poor outcomes [1,5,6,9,15,16]; however, few studies
have evaluated the role of particular adjuvant therapies 
according to risk group for revised 2009 FIGO stage IIIA dis-
eases. Here, we evaluated survival outcomes according to
risk factors and sought to determine the benefit of combined
modality treatment after surgery in the high-risk subset of
stage IIIA patients.
Materials and Methods
All patients with stage IIIA endometrial cancer treated
with surgery, followed by adjuvant RT or combined CTRT,
in Korea between January 1990 and December 2011 were
evaluated. All patients were staged based on the revised 2009
FIGO criteria for endometrial cancer. Patients eligible for
analysis had endometrioid adenocarcinoma only.
Nineteen patients with non-endometrioid type adenocar-
cinoma, such as papillary serous, clear cell, adenosquamous,
or carcinosarcoma were excluded. In addition, five patients
with only positive peritoneal cytology, and those who 
underwent adjuvant CT alone (n=3) or inadequate RT (n=2)
were also excluded. The remaining 93 stage IIIA patients
who underwent surgery followed by adjuvant RT alone or
combined CTRT were analyzed retrospectively. 
The clinical and pathologic data of 93 patients from 18 
institutions were collected. After approval by the Korean 
Radiation Oncology Group (KROG 13-17), the medical and
RT records of the patients were reviewed retrospectively.  
1. Treatment  
All patients underwent hysterectomy and bilateral salp-
ingo-oophorectomy with pelvic and/or aortic lymphadenec-
tomy, followed by postoperative RT or combined CTRT.
Pelvic lymph node dissection was performed in 77 patients
(82.8%) and paraaortic lymph node (PALN) dissection or
sampling was performed in 31 patients (33.3%). 
All patients underwent external pelvic RT, delivered to the
tumor bed and regional lymphatics with 10-MV photons
using the four-field box technique. The total dose to the
pelvis ranged from 45 Gy to 54 Gy in 1.8 Gy daily fractions,
5 days per week. Twenty-one patients (21.6%) underwent 
additional vaginal brachytherapy using Fletcher-Suit after-
loading applicators. Two to six fractions of 3-5 Gy were 
delivered to the vaginal surface or 5 mm from the vaginal
surface. Two patients (2.2%) were treated with an extended-
field RT encompassing a volume of PALN, usually located
at the T12-L1 interface. Another two patients received total
abdominal RT of 30 Gy in 1.5 Gy fractions followed by a
boost to the pelvis with the doses of 19.8 Gy or 24 Gy in 1.8
Gy fractions.
Adjuvant combined CTRT was performed in 36 patients
(38.7%). Thirty patients were treated with concurrent CTRT
(83.3%), four patients with CT followed by RT (11.1%), and
two patients with RT followed by CT (5.6%). Patients receiv-
ing adjuvant CT were treated with cisplatin-based CT (n=19,
52.8%), carboplatin plus paclitaxel (n=8, 22.2%), paclitaxel
alone (n=6, 16.7%), or other drugs (n=3, 8.3%). Adjuvant 
CT was delivered with a median of six cycles (range, 1 to 9
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cycles), although two patients received only one cycle, and
another two patients only received two cycles. Five patients
did not complete the full course of CT because of G3 hema-
tologic toxicity (n=2), patient refusal (n=1), or no available
data on toxicity (n=2). 
In adjuvant RT alone, the average treatment period was
42.9 days (range, 36 to 60 days) and 46.9 days (range, 35 to
117 days) for the CTRT group. No significant difference in
the RT period was observed between the two treatment
groups (p=0.057). 
2. Statistical analysis
Locoregional recurrence was defined as a recurrence in the
pelvis, vagina, or paraaortic lymphatic region. Failure was
defined as biopsy-proven recurrence or progression of dis-
ease on serial imaging studies. Time to recurrence and death
was calculated from the date of surgery until failure or death
from any cause. DFS was defined as alive without disease 
recurrence at the time of censoring. Survival curves were cal-
culated using the Kaplan-Meier method, and comparison of
the curves was performed using a log-rank test. The chi-
square test, Fisher exact test, and independent samples t test
were used for comparison of characteristics between the two
groups. Multivariable analysis was performed using the Cox
proportional hazards model. Statistical analyses were per-
formed using SPSS ver. 21 (IBM Co., Armonk, NY), and 
p-values less than 0.05 were considered statistically signifi-
cant.
Results
1. Patient characteristics and pattern of failure
The tumor and treatment characteristics of all 93 patients,
57 (61.3%) who received postoperative RT alone and 36
(38.7%) who received CTRT, are shown in Table 1. The 
median age of patients in the CTRT group was older than
that in the RT alone group. A larger portion of patients in the
CTRT group showed involvement of serosa (27.8% vs. 19.3%,
p=0.361) and lymphovascular space (30.6% vs. 15.8%,
p=0.214). 
A higher proportion of patients in the CTRT group under-
went paraaortic lymphadenectomy compared to the RT
alone group (52.8% vs. 21.1%, p=0.002). The extent of irradi-
ation field of adjuvant RT and vaginal brachytherapy did not
differ significantly in the two groups. 
The median follow-up period was 62 months (range, 3 to
188 months). Eight patients (14.0%) in the RT alone group
and 11 patients (30.6%) in the CTRT group relapsed during
the follow-up period (p=0.054) (Table 2). The majority of 
recurrences were distant metastases including abdominal 
recurrence, 75% (6/8) in the RT alone group and 81.8%
(9/11) in the CTRT group. In the RT alone group, one patient
developed combined local and distant metastases with pelvic
lymph node and liver metastasis.
2. DFS and OS
The 5-year OS and DFS were 93.7% and 79.0%, respec-
tively. Univariate analyses showed statistically significant
difference in DFS with regard to age (p < 0.001), tumor 
grade (p=0.029), and lymphovascular involvement (p=0.041)
(Table 3). No significant difference in OS (91.9% vs. 96.3%,
p=0.262) or DFS (82.4% vs. 74.1%, p=0.130) was observed 
between the RT alone group and the combined CTRT group.
Five-year DFS was lower in patients with serosal involve-
ment than in those without, but there was no statistical 
significance (81.5% vs. 67.2%, p=0.180). Involvement of 
adnexa did not show a significant relationship with DFS. Of
the 93 patients, 57 (61.3%) had solitary adnexal or serosal 
involvement. Patients with serosal involvement had a worse
7-year DFS (66.7%) compared to those with solitary adnexal
involvement (90.5%), but this difference did not reach statis-
tical significance (p=0.629).
The above mentioned variables (age ! 60 years, tumor
grade 2/3, and lymphovascular space involvement) for prog-
nosis in DFS were defined as risk factors. Of 77 patients with
available data for risk factors, 25 patients (32.5%) had no risk
factors, 30 (38.9%) had one, 16 (20.8%) had two, and six
(7.8%) had three. A significant correlation was observed 
between the number of risk factors and DFS. The 5-year DFS
was 91.7% in patients with no risk factors, 84.8% in patients
with one, 55.0% in patients with two, and 33.3% in patients
with three (p=0.001). The 5-year OS according to the number
of risk factors was 95.0% in patients with no risk factors,
92.0% in patients with one, 93.8% in patients with two, and
80.0% in patients with three (p=0.542). 
The patients were subgrouped according to low-risk 
(patients with no or one risk factor) and high-risk (patients
with two or three risk factors) groups. The proportion of
high-risk patients in the combined CTRT group was more
than twice that of the RT alone group (41.9% vs. 19.6%,
p=0.033). Thirty-seven patients (80.4%) in RT alone were clas-
sified as low risk and nine (19.6%) as high risk. In CTRT, 18
patients (58.1%) were classified as low risk, while 13 patients
(41.9%) as high risk. A significant reduction in 5-year DFS
was observed in the high-risk group (49.0% vs. 88.0%, 
p < 0.001) compared with the low-risk group (Fig. 1). 
Five-year OS was not significantly lower in the high-risk
group (90.7%) versus the low-risk group (93.5%) (p=0.618).
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For RT alone, 5-year DFS and OS were lower in the high-
risk group than in the low-risk group (66.7% vs. 84.6%,
p=0.133 and 77.8% vs. 93.5%, p=0.149, respectively), but the
differences did not reach statistical significance (Fig. 2). 
In the CTRT group, the low-risk group showed an improved
5-year DFS (94.4% vs. 38.5%, p=0.001) compared with the
high-risk group, but there was no significant difference in OS
(93.3% vs. 100%, p=0.465). 
3. Multivariate analysis
To examine the role of adjuvant multi-modality therapy,
the risk groups were analyzed according to treatment modal-
ities. No significant difference in 5-year OS (93.5% vs. 93.3%,
p=0.785) or DFS (84.6% vs. 94.4%, p=0.852) was observed 
between the RT alone group and the combined CTRT group
in the low-risk group. In the high-risk group, combined
CTRT showed a trend for improved 5-year OS (100% vs.
77.8%, p=0.086) compared with RT alone, but the difference
did not reach statistical significance. Combined CTRT did
Table 1. Clinical and pathologic characteristics in stage IIIA endometrial adenocarcinoma according to adjuvant modality
Characteristic All  (n=93) RT alone  (n=57) CTRT (n=36) p-value
Age, median (range, yr) 51 (25-83) 50 (25-83) 54 (35-75) 0.281
Age (yr)
< 60 74 (79.6) 46 (80.7) 28 (77.8) 0.733
! 60 19 (20.4) 11 (19.3) 8 (22.2)
Grade
I 41 (44.1) 28 (49.1) 13 (36.1) 0.291
II 30 (32.3) 15 (26.3) 15 (41.7)
III 20 (21.5) 12 (21.1) 8 (22.2)
Unknown 2 (2.2) 2 (3.5) 0 (
Serosal involvement
Negative 70 (75.3) 44 (77.2) 26 (72.2) 0. 361
Positive 21 (22.6) 11 (19.3) 10 (27.8)
Unknown 2 (2.2) 2 (3.5) 0 (
Adnexal involvement
Negative 16 (17.2) 11 (19.3) 5 (13.9) 0.501
Positive 77 (82.8) 46 (80.7) 31 (86.1)
Lymphovascular involvement
Negative 59 (63.4) 38 (66.7) 21 (58.3) 0.214
Positive 20 (21.5) 9 (15.8) 11 (30.6)
Unknown 14 (15.1) 10 (17.5) 4 (15.1)
Tumor sizea), mean (range, cm) 4.6 (0.4-12) 4.4 (1.5-12) 5.0 (0.4-10.2) 0.327
Lymph node dissection 
Pelvic LN dissection 77 (82.8) 44 (77.2) 33 (91.7) 0.072
Paraaortic LN dissection 31 (33.3) 12 (21.1) 19 (52.8) 0.002
Type of external beam radiotherapy
Whole pelvis 89 (95.7) 54 (94.7) 35 (97.2) 0.500
Whole pelvis+paraaortic field 2 (2.2) 1 (1.8) 1 (2.8)
Whole abdomen 2 (2.2) 2 (3.5) 0 (
Additional vaginal brachytherapy
No 72 (77.4) 46 (80.7) 26 (72.2) 0.341
Yes 21 (21.6) 11 (19.3) 10 (27.8)
CTRT sequence
Concurrent 30 (83.3)
Sequential 6 (16.7)
Values are presented as number (%) unless otherwise indicated. RT, radiotherapy; CTRT, chemoradiotherapy; LN, lymph
node. a)Data were available in 70 patients with measurable primary tumor.
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not affect 5-year DFS (38.5% vs. 66.7%, p=0.274) compared
with RT alone for the high-risk group.
In multivariate analysis including age, grade, lympohovas-
cular involvement, number of risk factors, and type of adju-
vant modality, more than one risk factor was the only pre-
dictor of worse DFS (hazard ratio [HR], 5.45; 95% confidence
interval [CI], 2.12 to 13.98; p < 0.001). In multivariate analysis
for OS, only old age was predictive of OS (HR, 5.8; 95% CI,
Table 2. Patterns of failure according to adjuvant treatment
Table 3. Factors affecting survival in univariate analysis
Treatment RT alone (n=57) CTRT (n=36) p-valuea)
Locoregional recurrence - 2 (18.2) -
Pelvic cavity only - 1 (
Pelvic LN+vagina - 1 (
Pelvic LN+paraaortic LN 1 (12.5) -
Distant metastasis 6 (75.0) 9 (81.8) -
Peritoneal seeding only 2 ( 2 (
Solid organs (liver, lung, vulva, etc.) 
Lung only 1 ( 4 (
Lung+other organ 1 ( 1 (
Vulva 1 ( 1 (
Other or multiple (liver, abd wall, and spleen) 1 ( 1 (
Combined LRR and DM 1 (12.5) - -
Total recurrence 8 (14.0) 11 (30.6) 0.054
Values are presented as number (%). RT, radiotherapy; CTRT, chemoradiotherapy; LN, lymph node; LRR, locoregional 
recurrence; DM, distant metastasis. a)Chi-square test.
Parameter Disease-free survival Overall survival
5-Year (%) p-value 5-Year (%) p-value
Age (< 60 yr vs. ! 60 yr)
< 60 86.6 < 0.001 96.7 0.028
! 60 48.9 81.4 
Grade (G1 vs. G2/3)
G1 90.0 0.029 94.4 0.387
G2/G3 68.9 93.3
LVI
No 83.2 0.041 91.9 0.699
Yes 57.9 94.4
Serosal involvement
No 81.5 0.180 91.8 0.747
Yes 67.2 100
Adnexal involvement
No 73.8 0.790 100 0.991
Yes 79.1 92.5
Size (diameter, cm)
" 5 84.0 0.175 95.5 0.482
> 5 77.3 89.4
Adjuvant treatment
RT alone 82.4 0.130 91.9 0.262
CTRT 74.1 96.3
LVI, lymphovascular involvement; RT, radiotherapy; CTRT, chemoradiotherapy.
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1.15 to 29.61; p=0.034). In multivariate analysis, combined
CTRT did not show a statistical difference compared to RT
alone in DFS or OS (Table 4).
4. Treatment related toxicities
Twelve patients (33.3%) in the CTRT group experienced
grade 3-4 acute toxicity. Grade 3-4 acute hematologic toxici-
ties were observed in 11 patients in the CTRT group and a
grade 3 acute intestinal obstruction was found in one patient.
In the RT alone group, one patient (1.8%) treated with 
extended-field RT had grade 4 acute hematologic toxicity.
No patients in the CTRT group had grade 3-4 late toxicity
and one patient in the RT alone group treated with whole 
abdominal irradiation had a grade 3 late leg edema.
Discussion
The current study showed the impact of a number of risk
factors for stage IIIA endometrioid adenocarcinoma. Patients
with more than one risk factor (high-risk group) had a worse
prognosis. Indeed, more than one risk factor was the only
strong negative prognostic factor in multivariate analysis.
Patients in the high-risk group were 4 to 5 times more likely
to develop a distant metastasis compared to those in the low-
risk group (40.9% vs. 9.1%, p < 0.001), therefore, the addition
of more intense systemic therapy to those in the high-risk
group may improve the outcome. The current study showed
that combined CTRT showed a trend with an improved 
5-year OS (100% vs. 77.8%, p=0.086) compared with RT
alone, although CTRT did not affect 5-year DFS compared
with RT alone for the high-risk group. Several studies have
suggested that combined CTRT can provide additional ben-
efits compared with CT or RT alone [10-13]. The retrospective
study in stage III and IV endometrial cancer by Alvarez Sec-
ord et al. [13] reported that adjuvant CT alone was associated
with poor 3-year OS (33%) and progression-free survival
(19%) compared to either RT alone (70% and 59%) or com-
bined therapy (79% and 62%). In a multicenter retrospective
study conducted with 78 patients with stage III endometrial
cancer treated with adjuvant CT and/or RT, the 3-year 
relapse-free survival rates were 86.5% for the combined
CTRT group, 65.8% for the CT alone, and 44.1% for RT alone,
suggesting that combined CTRT modality may induce an 
advantage in relapse-free survival compared to RT or CT
alone [17]. Randomized trials were conducted for compari-
son of sequential CTRT with RT alone. The first trial was run
by the Italian Oncology Group with 153 patients (IIB-IIIC,
65% stage III), and the second by the Nordic Society of 
Gynaecological Oncology/European Organisation for the
Research and Treatment of Cancer, which included patients
with mainly high-risk early stage disease (only 1.6% stage
III). In the Italian trial, no statistically significant difference
in DFS or OS was observed between treatment groups. How-
ever, in joint pooled analysis in these two randomized trials,
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Fig. 1. Kaplan-Meier survival curve of disease-free survival (A) and overall survival (B) according to the low-risk group
with no or one risk factor and the high-risk group with two or three risk factors (risk factor: age ! 60 or ! G2 or lymphovas-
cular space invasion).
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Fig. 2. Subgroup analysis according to treatment modality. Disease-free survival and overall survival in the radiotherapy
alone group (A) and the chemoradiotherapy group (B). The low-risk group with no or one risk factor and the high-risk group
with two or three risk factors (risk factor: age ! 60 years or ! G2 or lymphovascular space invasion).
Table 4. Multivariate analysis
Parameter Disease-free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Age (< 60 yr vs. ! 60 yr) - 0.340 5.83 (1.15-29.61) 0.034
Grade (G1 vs. G2G3) - 0.903 - 0.834
LVI (no vs. yes) - 0.884 - 0.437
No. of risk factorsa) (< 2 vs. ! 2) 5.45 (2.12-13.98) < 0.001 - 0.093
RT alone vs. CTRT - 0.488 - 0.177
HR, hazard ratio; CI, confidence interval; LVI, lymphovascular space invasion; RT, radiotherapy; CTRT, chemoradiotherapy.
a)Risk factor: age ! 60 years or ! G2 or LVI.
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sequential addition of CT to RT improved at least progres-
sion-free survival (78% vs. 69%, p=0.009), and trended a ben-
efit of overall survival (82% vs. 75%, p=0.07) compared with
RT alone [12]. 
An important question is whether or not it is reasonable to
recommend adjuvant RT alone without chemotherapy in
low-risk patients. Prior study has suggested that a subgroup
of women with stage IIIA who have endometrioid tumor, no
lymphovascular space involvement, and positive peritoneal
cytologic finding only show an excellent prognosis [15].
Havrilesky et al. [6] found that among 24 patients with peri-
toneal cytology only, non-serous histology, and grade 1-2
disease, no recurrence was found in 12 patients receiving 
adjuvant treatment, while one patient showed recurrence
without adjuvant treatment. Our study included patients 
according to the 2009 FIGO staging system and excluded
those with peritoneal cytology only. For 25 patients with no
risk factors, 17 patients (68%) were treated with adjuvant RT
alone and eight patients (32%) with adjuvant combined
CTRT, resulting in excellent 5-year DFS (91.7%) and OS
(95.0%), respectively. No difference in DFS and OS was 
observed between RT alone and the CTRT group. Thus, a
subset of stage IIIA patients with no risk factors might be
treated with adjuvant RT alone. 
Several studies have reported that patients with extrauter-
ine spread limited to the adnexa showed favorable 5-year
DFS rates, ranging from 71% to 89.6% [3,18,19]. By contrast,
serosal involvement had a relatively poor prognosis [15,20].
A retrospective study of 15 patients with solitary serosal 
invasion had a poor 5-year DFS (41.5%) due to the high inci-
dence of distance metastases [20]. A multicenter retrospec-
tive comparative analysis in Netherlands published the
outcomes for 67 patients with stage IIIA endometrial carci-
noma, evaluating differences in outcome between serosa and
adnexal involvement [18]. Those with involvement of the
serosa alone had a worse 7-year distant metastasis-free sur-
vival (58.7%) compared to adnexal involvement alone
(72.7%), but this difference was not significant (p=0.399). 
Authors concluded that either adnexal or serosal involve-
ment showed a comparable disease-specific survival and
only presence of lymphovascular invasion was significant in
multivariate analysis (HR, 3.6; p=0.038). The current study
was composed of a relatively large homogeneous subgroup
of surgically staged IIIA patients with only adnexal or serosal
involvement. Of the 93 patients in our study, 57 (61.3%) had
solitary adnexal or serosal involvement. Consistent with pre-
vious studies, patients with serosal involvement had a worse
7-year DFS (66.7%) compared to those with solitary adnexal
involvement (90.5%) (p=0.629).
In this multicenter analysis, we failed to demonstrate 
additional benefit of combined adjuvant CTRT compared
with adjuvant RT alone for stage IIIA endometrial cancer.
While these findings might suggest a comparable survival
outcome between combined CTRT and RT alone groups, our
study is limited by the difference of high-risk features 
between the groups. Although there was no statistically sig-
nificant difference in median age, grade, and lymphovascu-
lar involvement between the RT alone group and the
combined CTRT group, the CTRT groups did show a trend
with an older age, higher grade, and more involvement of
lymphovascular space than the RT alone group. In addition,
a subset of patients with more than one risk factor, the high-
risk group, in the combined CTRT group was more than
twice that of the RT alone group (41.9% vs. 19.6%, p=0.033).
These factors might lead to comparable survival outcomes
between the RT alone group and the combined CTRT group.
Another limitation of this study is the retrospective design
with heterogeneity of the CT agent, sequence of combined
CTRT and surgical technique with paraaortic lymphadec-
tomy. This variability leads to difficulty in determining the
additional benefit of CTRT in stage IIIA endometrioid ade-
nocarcinoma.  
For gynecologic Oncology group 258 (GOG258), the cur-
rent phase III randomized trial for adjuvant modality, the
CTRT followed by carboplatin+paclitaxel is being compared
to combination of carboplatin and paclitaxel in stage III and
IVA patients. Multi-center randomized trials are required to
further evaluate the role of adjuvant combined modality, 
according to risk groups, particularly in stage IIIA endome-
trial adenocarcinoma which is an uncommon entity.
Conclusion
In conclusion, the current study showed a favorable out-
come in a subset of low-risk patients compared to the high-
risk group in stage IIIA endometrioid adenocarcinoma
treated with adjuvant RT alone or adjuvant combined CTRT.
We found that patients classified as high risk (! 2 risk factors)
showed a significant reduction in 5-year DFS compared with
the low-risk group (49.0% vs. 88.0%, p < 0.001) with an 
increase in the development of distant metastasis (40.9% vs.
9.1%, p < 0.001). We identified a subset of stage IIIA patients
without risk factors who might be reasonable candidates for
adjuvant RT alone.
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